Hypertension Drugs Market size was valued at USD 21.85 billion in 2024 and is expected to cross USD 37.11 billion by the end of 2037, registering more than 4.3% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of hypertension drugs is estimated at USD 22.58 billion. The market is expanding due to an increase in hypertension cases around the world, as it is a condition caused by chronic kidney infection, apnea, and other factors, and is the most common health disorder among the majority of the global population. As a result, the high demand for hypertension drugs is attributed to the high sales volume of hypertension drugs and their available treatment options.
The growing prevalence of insomnia across the globe is believed to fuel market growth. For instance, insomnia is a common sleep disorder that makes it difficult to fall asleep or sometimes causes a person to wake up early. Insomnia is noticed to be interlinked with hypertension and beta-blockers are highly used to treat insomnia heavily across the globe. For instance, it was stated that in every 3 adults across the globe, one of them has insomnia.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
4.3% |
|
Base Year Market Size (2024) |
USD 21.85 billion |
|
Forecast Year Market Size (2037) |
USD 37.11 billion |
|
Regional Scope |
|
Drug Class (Alpha & Beta Blockers, Diuretics, Angiotensin Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, Renin Inhibitors)
The diuretics segment is estimated to gain a robust market share of 48% in the coming years owing to its high preference among the majority of patients for hypertension treatment. Diuretics, sometimes known as water pills, help the body get rid of surplus fluids and are frequently tried as the first drug for hypertension. They are preferred by patients owing to their effectiveness, inexpensive price, and few adverse effects. For instance, Chlorthalidone is one of the most often prescribed thiazide diuretics, which has been FDA-approved since 1960. Further, studies have shown that 1 in every 3 adults having hypertension was reported to take diuretics, which is anticipated to drive the growth of the diuretics segment during the forecast period.
Type (Systemic, Pulmonary)
The pulmonary segment in the hypertension drugs market is set to garner a notable share in the near future. Pulmonary hypertension is described as high blood pressure in the blood vessels that are responsible for supplying blood to pulmonary arteries. Pulmonary disease can be life-threatening since it can damage the right side of the heart. For instance, around 500 to 100 new cases of pulmonary arterial hypertension are diagnosed in the United States every year which sums up to nearly 12 cases per million people.
Furthermore, the systemic segment is also anticipated to hold a significant share of the hypertension drug market during the forecast period. Systemic hypertension is also another form of high blood pressure in arteries carrying blood from the heart to the body.
Our in-depth analysis of the global market includes the following segments:
|
Drug Class |
|
|
Type |
|
|
Distribution Channel |
|
North American Market Forecast
Hypertension drugs market in North America is predicted to account for the largest share of 30% by 2037, impelled by the presence of leading market players in the region that manufacture and market hypertension drugs. For instance, the presence of leading market players may result in the development of innovative drugs for hypertension and improved treatment options for patients in the region.
APAC Market Statistics
The APAC hypertension drugs market is estimated to be the second largest, during the forecast timeframe led by the rise in the geriatric population, especially in countries such as China, India, and Japan. The elderly population is more prone to chronic conditions such as high blood pressure which requires long-term management. This extended treatment period is expected to increase the demand for hypertension drugs in the region. According to the World Health Organization (WHO), owing to rising life expectancy and falling birth rates, 28% of China's population is expected to be over 60 by 2040.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?